Co-administration of indacaterol and tiotropium bromide for the treatment of chronic obstructive pulmonary disease and bronchiectasis, and effect on IL-8 and CRP levels

Abstract

Purpose: To investigate the efficacy of indacaterol plus tiotropium bromide in chronic obstructive pulmonary disease (COPD) complicated by bronchiectasis and the impact on IL-8 and C reactive protein (CRP) levels.Methods: Sixty enrolled patients with COPD and bronchiectasis who received treatment in Yantai Qishan Hospital, Yuyan, China from June 2017 to December 2019 were randomly allocated to group A (n = 30) and group B (n = 30). Group A received inhalation of indacaterol plus tiotropium bromide. Group B received only tiotropium bromide inhalation therapy. Therapeutic effects and appropriate serum indicators were compared.Results: Maximal mid-expiratory flow (MMF), maximal voluntary ventilation (MVV), and forced expiratory volume in one second (FEV1.0) levels of the patients were significantly elevated, and group A showed a significantly higher values than group B (p < 0.05). The serum levels of IL-8, CRP, and serum calcitonin (PCT) in both groups were lower than before treatment, but the decrease in group A was significantly greater than that in group B (p < 0.05). The SaO2, PaO2, and PaO2/FiO2 levels in both groups increased, but the increase in group A was higher than that in group B (p < 0.05). Group A showed a significantly lower total incidence of complications than group B (p < 0.05).Conclusion: Indacaterol plus tiotropium bromide produced significant effects in the treatment of COPD with bronchiectasis, which ameliorate lung function and inflammation status in the body and therefore have the potential of being utilized in clinical practice.